[Additional omega-3-fatty acids. Infarct mortality gets reduced].
D002986:Clinical Trials as Topic; D016757:Death, Sudden, Cardiac / Q000517:prevention & control; D004281:Docosahexaenoic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D009203:Myocardial Infarction / Q000401:mortality* / Q000517:prevention & control; D010919:Placebos; D012307:Risk Factors; D013997:Time Factors
D004338:Drug Combinations; D010919:Placebos; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid; C405603:Omacor
Zusätzlich Omega-3-Fettsäuren. Infarkt-Sterblichkeit Iässt sich reduzieren.